CANNDU

Canndu is a biotechnology company focused on the development of novel cancer therapeutics, specifically targeting the p53 pathway. The company leverages the expertise of its founders in p53 biology to design small molecules that can restore the function of mutant p53 or stabilize wild-type p53 in cancer cells. By inhibiting the interaction between p53 and its negative regulator MDM2, Canndu aims to trigger apoptosis in tumor cells while sparing healthy tissue. The company's research is primarily in the pre-clinical stage, with a focus on identifying potent and selective lead compounds for various solid tumor indications.